Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Phase II Clinical Study of Novel Ophthalmic Product

September 20th, 2006

Phase II Clinical Study of Novel Ophthalmic Product

Abstract:
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP).

Source:
pipelinereview.com

Bookmark:

Related Links

pSivida

Related News Press

Nanomedicine

Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013

Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013

Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013

Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013

Announcements

Kinks and curves at the nanoscale: New research shows 'perfect twin boundaries' are not so perfect May 20th, 2013

Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013

NanoInk, Inc. Assets To Be Sold May 18th, 2013

Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013